- Tytuł:
- A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model
- Autorzy:
- Źródło:
- Cancer Immunology, Immunotherapy. 72(9):2939-2948
Czasopismo naukowe